EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if the investigational drug EL625, when combined
with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide), is effective in
Persistent Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)